title: [Human African trypanosomiasis in Ivory Coast: biological characteristics after treatment. 812 cases treated in the Daloa focus (Ivory Coast)].
abstract: The treatment and post therapeutic follow up of patients diagnosed with HAT are important for HAT control. A longitudinal survey was implemented in the focus of Daloa (Côte d'Ivoire). A total of 812 patients infected with Trypanosoma brucei gambiense in meningoencephalitic stage and treated with melarsoprol were included, this study pointed out the biological characteristics of patients after treatment. The relapse occurs between 1 and 24 months after treatment. It is essentially neurological, and characterised by the presence in the CSF of antibodies, by the increase of cell count compared with value immediately after treatment, or by the presence of trypanosomes. The cure can be confirmed from 18 months after treatment, and is characterised by the absence of antibodies and trypanosomes in the CSF, by a normal cell count and a normal proteinorachy. Biological scares were recorded on some of the patients after 18 months of follow up, but no relapse occurred among them.
authors.affiliation: Projet de recherches cliniques sur la trypanosomiase, BP 1425 Daloa, Côte d'Ivoire.
authors.forename: T W
authors.initials: TW
authors.lastname: Miezan
authors.forename: N N
authors.initials: NN
authors.lastname: Dje
authors.forename: F
authors.initials: F
authors.lastname: Doua
authors.forename: F
authors.initials: F
authors.lastname: Boa
mesh_terms: D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood / Q000134:cerebrospinal fluid; D002555:Cerebrospinal Fluid / Q000166:cytology / Q000469:parasitology; D002556:Cerebrospinal Fluid Proteins / Q000032:analysis; D007560:Cote d'Ivoire; D005500:Follow-Up Studies; D006801:Humans; D008549:Melarsoprol / Q000627:therapeutic use*; D012008:Recurrence; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D014344:Trypanocidal Agents / Q000627:therapeutic use*; D014347:Trypanosoma brucei gambiense / Q000276:immunology; D014353:Trypanosomiasis, African / Q000145:classification / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism
chemical_list: D000913:Antibodies, Protozoan; D002556:Cerebrospinal Fluid Proteins; D014344:Trypanocidal Agents; D008549:Melarsoprol
vernacular_title: Trypanosomose humaine africaine en Côte d'Ivoire: caractéristiques biologiques après traitement. A propos de 812 cas traités dans le foyer de Daloa (Côte d'Ivoire).